| scholarly article | Q13442814 |
| P50 | author | Peter J Turnbaugh | Q37391152 |
| Andrew Patterson | Q47316518 | ||
| P2860 | cites work | Enteric microbiome metabolites correlate with response to simvastatin treatment | Q21135141 |
| Moving pictures of the human microbiome | Q21999542 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Human gut microbiome viewed across age and geography | Q24602950 | ||
| Rapid determination of 16S ribosomal RNA sequences for phylogenetic analyses | Q24609392 | ||
| QIIME allows analysis of high-throughput community sequencing data | Q24616873 | ||
| Structure, function and diversity of the healthy human microbiome | Q24626370 | ||
| Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis | Q24629045 | ||
| Innate immunity and intestinal microbiota in the development of Type 1 diabetes | Q24647312 | ||
| A core gut microbiome in obese and lean twins | Q24649648 | ||
| Comparative metagenomics revealed commonly enriched gene sets in human gut microbiomes | Q24652180 | ||
| Do interactions between gut ecology and environmental chemicals contribute to obesity and diabetes? | Q27010006 | ||
| Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota | Q27660452 | ||
| Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme | Q27665609 | ||
| Bacteria of the human gut microbiome catabolize red seaweed glycans with carbohydrate-active enzyme updates from extrinsic microbes | Q27675118 | ||
| An obesity-associated gut microbiome with increased capacity for energy harvest | Q27860515 | ||
| The gut microbiota as an environmental factor that regulates fat storage | Q28131676 | ||
| FXR is a molecular target for the effects of vertical sleeve gastrectomy | Q28236848 | ||
| Towards the human intestinal microbiota phylogenetic core | Q28251918 | ||
| Developing a metagenomic view of xenobiotic metabolism | Q28273307 | ||
| Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment | Q28296759 | ||
| Evolution of mammals and their gut microbes | Q28755326 | ||
| The antibiotic resistome: the nexus of chemical and genetic diversity | Q29544028 | ||
| Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat | Q35004010 | ||
| Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. | Q35050169 | ||
| Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. | Q35062300 | ||
| Ecological modeling from time-series inference: insight into dynamics and stability of intestinal microbiota | Q35069150 | ||
| Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice | Q35913146 | ||
| Metabolic risk during antipsychotic treatment | Q36095376 | ||
| Host remodeling of the gut microbiome and metabolic changes during pregnancy | Q36421887 | ||
| Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta | Q37077458 | ||
| Quantitative UPLC-MS/MS analysis of the gut microbial co-metabolites phenylacetylglutamine, 4-cresyl sulphate and hippurate in human urine: INTERMAP Study | Q37087386 | ||
| The long-term stability of the human gut microbiota | Q37217949 | ||
| The gastrointestinal microbiota as a site for the biotransformation of drugs | Q37235756 | ||
| Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism | Q37318311 | ||
| Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. | Q37503122 | ||
| Arsenic exposure perturbs the gut microbiome and its metabolic profile in mice: an integrated metagenomics and metabolomics analysis | Q37627585 | ||
| Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics | Q37679135 | ||
| Gut microbiome phenotypes driven by host genetics affect arsenic metabolism. | Q37719316 | ||
| Toxicological significance of azo dye metabolism by human intestinal microbiota | Q37971640 | ||
| Phylogenetic stains: ribosomal RNA-based probes for the identification of single cells | Q38345041 | ||
| Metabolism of foreign compounds by gastrointestinal microorganisms | Q39934307 | ||
| Medicines from microbiota | Q44469787 | ||
| Ecology drives a global network of gene exchange connecting the human microbiome. | Q51171065 | ||
| Is It Time for a Metagenomic Basis of Therapeutics? | Q57011994 | ||
| The phylogeny of prokaryotes | Q58425529 | ||
| Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns | Q29547261 | ||
| Diet rapidly and reproducibly alters the human gut microbiome | Q29547454 | ||
| A metagenome-wide association study of gut microbiota in type 2 diabetes | Q29547726 | ||
| Gut microbiota from twins discordant for obesity modulate metabolism in mice | Q29614796 | ||
| Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity | Q29615051 | ||
| Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5 | Q29615053 | ||
| Succession of microbial consortia in the developing infant gut microbiome | Q29615811 | ||
| Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders | Q29617111 | ||
| Richness of human gut microbiome correlates with metabolic markers | Q29617365 | ||
| Gut microbiota composition correlates with diet and health in the elderly | Q29617441 | ||
| Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation | Q29617796 | ||
| Gut microbiomes of Malawian twin pairs discordant for kwashiorkor | Q30418022 | ||
| Temporal dynamics of the human vaginal microbiota | Q30541808 | ||
| Biotechnological prospects from metagenomics | Q30960118 | ||
| The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide | Q31144277 | ||
| Dynamics and associations of microbial community types across the human body | Q31158807 | ||
| Getting to the core of the gut microbiome | Q33427783 | ||
| Intestinal microbiota regulate xenobiotic metabolism in the liver | Q33501739 | ||
| Dominant and diet-responsive groups of bacteria within the human colonic microbiota | Q33649520 | ||
| Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. | Q33718086 | ||
| Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics | Q33779249 | ||
| Organismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins | Q33841913 | ||
| Xenobiotic metabolism: a look from the past to the future | Q33946776 | ||
| Bile salt hydrolase activity and resistance to toxicity of conjugated bile salts are unrelated properties in lactobacilli | Q33990013 | ||
| Detecting novel associations in large data sets | Q34102548 | ||
| Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease | Q34241773 | ||
| A core human microbiome as viewed through 16S rRNA sequence clusters | Q34311676 | ||
| Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics | Q34311685 | ||
| Genomic variation landscape of the human gut microbiome | Q34316353 | ||
| Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist | Q34326973 | ||
| Melamine-induced renal toxicity is mediated by the gut microbiota | Q34327763 | ||
| Gut metagenome in European women with normal, impaired and diabetic glucose control | Q34347521 | ||
| Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: a cross-sectional study | Q34520269 | ||
| A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets | Q34550721 | ||
| Hippurate: the natural history of a mammalian-microbial cometabolite. | Q34559745 | ||
| An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice | Q34785134 | ||
| Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. | Q34996610 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 761-768 | |
| P577 | publication date | 2014-08-21 | |
| P1433 | published in | Cell Metabolism | Q1254684 |
| P1476 | title | Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology | |
| P478 | volume | 20 |
| Q62918821 | A Probe-Enabled Approach for the Selective Isolation and Characterization of Functionally Active Subpopulations in the Gut Microbiome. |
| Q36136449 | An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. |
| Q88646044 | Broad collateral damage of drugs against the gut microbiome |
| Q34470083 | Cancer and the microbiota |
| Q53285267 | Chemical Risk Assessment: Traditional vs Public Health Perspectives. |
| Q92482341 | Epithelial delamination is protective during pharmaceutical-induced enteropathy |
| Q64982979 | Getting Our Fingers on the Pulse of Slow-Growing Bacteria in Hard-To-Reach Places. |
| Q97423700 | Live Biotherapeutic Products, A Road Map for Safety Assessment |
| Q35847464 | Microbiome to Brain: Unravelling the Multidirectional Axes of Communication |
| Q35953810 | Signaling in Host-Associated Microbial Communities. |
| Q36026067 | Snapshot on a Pilot Metagenomic Study for the Appraisal of Gut Microbial Diversity in Mice, Cat, and Man |
| Q90865084 | The gut microbiome and aquatic toxicology: An emerging concept for environmental health |
| Q46416641 | The influence of rosuvastatin on the gastrointestinal microbiota and host gene expression profiles. |
| Q30248605 | The intestinal microbiome and surgical disease. |
| Q36038992 | The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions |
| Q37058619 | Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children |
Search more.